Cerluten vs Ovagen

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene expression regulatory mechanisms. Like other Khavinson bioregulator peptides, cerluten is proposed to reach target neuronal cells via amino acid transporter uptake — including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT) — and to modulate transcriptional activity in aging or damaged neural tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport via POT and LAT carriers and demonstrated gene expression regulatory effects across multiple tissue types, providing the class-level mechanistic framework within which cerluten's neuronal effects are proposed. Cerluten has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Cerluten dosing and respiratory applications Cerluten is classified as a bronchial tissue bioregulator in the Khavinson peptide research tradition, proposed to act on bronchial epithelial cells via amino acid transporter uptake and modulate gene expression related to respiratory tissue maintenance and oxidative stress response in aging airways. Preclinical and observational research in Eastern European clinical settings has examined cerluten in contexts of chronic bronchitis, age-related decline in respiratory function, and COPD support, with proposed mechanisms including anti-inflammatory gene regulation and bronchial epithelial cell cytoprotection. Standard Khavinson-class dosing protocols use oral capsule formulations in 10–20 day cycles at 5–10mg per cycle (divided doses), followed by rest intervals — consistent with the gene-regulatory rather than continuous-receptor-occupancy mechanism proposed for this peptide class. Independent peer-reviewed clinical trial evidence specific to cerluten is limited; efficacy data comes primarily from Khavinson Institute publications and observational reports. Cerluten is available from specialty Eastern European supplement and peptide vendors and is not approved by the FDA or EMA as a pharmaceutical. It is distinct from Chonluten, which targets lung parenchyma rather than bronchial epithelial tissue.

Liver-targeted peptide complex modulating hepatocyte gene expression. Supports liver cell regeneration, enzyme function normalization, and hepatic protein synthesis.

Ovagen is a Khavinson-class peptide bioregulator derived from ovarian tissue, developed through Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore gene expression and physiological function in aging ovarian tissue by interacting with chromatin regulatory elements in target cells. As an ovarian tissue-derived bioregulator, Ovagen is positioned within the Khavinson framework as a compound designed to modulate transcription in Leydig and granulosa cells, potentially influencing estrogen synthesis, follicular function, and reproductive aging; the class-level mechanistic research has characterized how short Khavinson peptides bind DNA regulatory sequences to activate tissue-specific gene expression programs. Published research on the Khavinson peptide bioregulator class as a whole documents the systematic discovery and characterization of organ-specific peptides, with class-level evidence from animal models and human observational studies demonstrating restorative effects on tissue-specific physiological parameters across multiple organ systems. Ovagen has no FDA approval and no approved indication in any Western jurisdiction; no indexed PubMed studies specifically characterize ovagen's clinical outcomes in human subjects, and the compound is available only through the Russian bioregulator market under the class-level evidence framework established by the Khavinson group's published research.